, Tracking Stock Market Picks
Enter Symbol:
Avanir Pharmaceuticals (AVNR) [hlAlert]

up 423.45 %

Avanir Pharmaceuticals (AVNR) rated Outperform with price target $13 by Wedbush

Posted on: Tuesday,  Nov 2, 2010  8:25 AM ET by Wedbush

Wedbush rated Outperform Avanir Pharmaceuticals (NASDAQ: AVNR) on 11/02/2010. Previously Wedbush rated Outperform Avanir Pharmaceuticals (NASDAQ: AVNR) on 04/29/2010.,
when the stock price was $3.24. Since then, Avanir Pharmaceuticals has gained 423.46% as of 01/12/2015's recent price of $16.96.
If you would have followed the previous Wedbush 's recommendation on AVNR, you would have gained 423.45% of your investment in 1719 days.

Avanir Pharmaceuticals is a pharmaceutical company focused on developing, acquiring and commercializing therapeutic products for the treatment of chronic diseases. The Company?s product candidates address therapeutic markets that include the central nervous system and inflammatory diseases. Its principal product candidate, Zenviatm (dextromethorphan hydrobromide/quinidine sulfate), is in Phase III clinical development for the treatment of pseudobulbar affect (PBA) and diabetic peripheral neuropathic pain (DPN pain). The Company?s first commercialized product, docosanol 10% cream, (sold as Abreva by its marketing partner GlaxoSmithKline Consumer Healthcare in North America) is an over-the-counter treatment for cold sores that has been approved by the United States Food and Drug Administration (FDA).

Wedbush is Headquartered in Los Angeles, California with over 90 offices and more than 125 correspondent offices, our commitment to providing relentless, customized service is the foundation of our consistent growth. We deliver superior investment ideas and products through exceptional customer care, financial security, continuity and advanced technology.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
11/2/2010 8:25 AM Buy
4.34 13.00
as of 12/31/2010
1 Week down  -2.58 %
1 Month down  -2.58 %
3 Months up  29.78 %
1 YTD down  -4.60 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
4/29/2010 9:25 AM Buy
3.24 9.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy